Ko nozīmē “Notīrīt”?
Dzīvniekam nav mutācijas. Tas neattīstīs slimību un nenodos to tālāk.
Suns Suņu vairāku sistēmu deģenerācija Kerry Blue Terrier (CMSD-KBT)
The Canine Multiple System Degeneration (CMSD) DNA test is essential for Kerry Blue Terrier owners to ensure their dogs' health. CMSD is a hereditary neurological disorder affecting coordination and movement in Kerry Blue Terriers. Early genetic testing helps identify carriers and affected dogs, enabling responsible breeding decisions. By using the CMSD DNA test, breeders can reduce the risk of passing this debilitating condition to future generations. This test provides accurate, reliable results, promoting the well-being of your Kerry Blue Terrier. Protect your dog’s health with the CMSD DNA test today. Regular screening supports a healthier, happier canine companion.
Saīsinājums: CMSD-KBT
Analizētā mutācija: SERAC1 c.1536G>A
Mantojums: Autosomāls recesīvs
Akronīms
CMSD-KBT
Novērotā biežums
Klīniskā smaguma pakāpe
Klīniskā klasifikācija
Neiroloģiskas slimības
Analizēta mutācija
SERAC1 c.1536G>A
p.(Trp512*)
p.(Trp512*)
Mantojuma veids
Autosomāls recesīvs
Testa kopsavilkums:
Canine Multiple System Degeneration (CMSD) is a genetic disorder affecting Kerry Blue Terriers, causing progressive neurological decline. A DNA test is available to identify carriers and affected dogs, helping breeders make informed decisions. Early detection through testing can prevent the spread of this debilitating condition within the breed. Responsible breeding practices rely on these genetic insights to maintain healthy Kerry Blue Terrier populations. Overall, the CMSD DNA test is a valuable tool for canine health management.
Pieejams no iepakojuma: Basic
Šis DNS tests ir iekļauts, sākot no mūsu iepakojuma Basic — un arī ir daļa no iepakojumiem Basic, Standard, Advanced, Complete.
Skatīt DNS testu pakotnes →Izvēlieties iepakojumu, kas vislabāk atbilst jūsu dzīvnieku audzēšanas vai veselības stratēģijai.
Understanding Canine Multiple System Degeneration in Kerry Blue Terriers (CMSD-KBT)
Canine Multiple System Degeneration (CMSD) is a progressive neurological disorder that primarily affects Kerry Blue Terriers. This condition is characterized by the degeneration of multiple systems within the nervous system, leading to a range of debilitating symptoms that can significantly impact the quality of life of affected dogs.
Symptoms of CMSD-KBT
The symptoms of CMSD-KBT typically manifest in early to mid-adulthood, although the age of onset can vary. Common signs include balance problems, difficulty walking, and a general lack of coordination. As the disease progresses, affected dogs may exhibit muscle weakness, tremors, and a decline in overall mobility. In some cases, dogs may also experience changes in behavior, such as increased anxiety or a reluctance to engage in normal activities.
Pathophysiology of CMSD-KBT
The underlying cause of CMSD-KBT lies in genetic mutations that affect the nervous system's ability to function properly. These mutations lead to the degeneration of nerve cells, which in turn causes a breakdown of communication between the brain and the body. This disruption results in the clinical symptoms observed in affected dogs. Understanding the genetic basis of CMSD-KBT is crucial for breeders and owners, as it allows for informed decisions regarding breeding practices and the management of affected animals.
Management and Care for Affected Dogs
While there is currently no cure for CMSD-KBT, management strategies can help improve the quality of life for affected dogs. Regular veterinary check-ups are essential for monitoring the progression of the disease and addressing any health concerns that arise. Physical therapy and rehabilitation exercises can assist in maintaining mobility and strength. Additionally, providing a safe and supportive environment can help dogs cope with their symptoms and enhance their overall well-being.
Secinājums
Canine Multiple System Degeneration in Kerry Blue Terriers is a serious condition that requires attention from dog owners and breeders. By understanding the symptoms, underlying causes, and management strategies associated with CMSD-KBT, stakeholders can work towards improving the lives of affected dogs while making informed breeding decisions to reduce the prevalence of this condition in the breed.
Pārbaudei atzītā šķirne: Suņu vairāku sistēmu deģenerācija Kerry Blue Terrier (CMSD-KBT)
- Kerry Blue Terrier
🧬 Interpretation of genotypes CMSD-KBT
Genotips
Statuss
🟡 N/N
Nepārvadātājs — bez riska
🟡 N/CMSD-KBT
Pārvadātājs — bez riska
❌ CMSD-KBT/CMSD-KBT
Ietekmētie — apdraudēti
FAQ: izpratne par interpretāciju
Vai “pārvadātājs” ir nopietns?
Nē. Dzīvnieks parasti ir vesels, bet var pārnest mutāciju uz savu pēcnācēji.
Ko darīt, ja dzīvnieks ir “ietekmēts”?
Tam ir divas mutācijas kopijas. Klīniskās pazīmes ir gaidāmas atkarībā no slimība. To nevajadzētu audzēt.
Kāpēc pastāv atšķirības starp vīrieti/sievieti?
Dažas slimības ir saistītas ar dzimumu, tāpēc to izpausme atšķiras atkarībā no dzīvnieka dzimums.
Paredzēt pēcnācējus
N/N (neparvadatajs)
N/CMSD-KBT (Pārvadātājs)
CMSD-KBT/CMSD-KBT (Ietekmētais)
Bieži uzdotie jautājumi par DNS testu
Ko atklāj šis DNS tests?
This DNA test detects the mutation associated with Canine Multiple System Degeneration In Kerry Blue Terrier (CMSD-KBT) in order to identify clear, carrier, or at-risk animals.
Kāpēc pārbaudīt vaislas dzīvnieku?
DNS testēšana palīdz selekcionāriem plānot drošāku pārošanos un samazina mutācijas pārnešanas risku pēcnācējiem.
Kāds ir šī testa mantojuma veids?
Šim testam ziņotais mantojuma režīms ir autosomāls recesīvs.
Kura mutācija tiek analizēta šajā testā?
This test analyses the mutation SERAC1 c.1536G>A.
Vai pārvadātājs dzīvnieks noteikti ir ietekmēts?
Nav obligāti. Interpretācija ir atkarīga no mantojuma modeļa un iegūtā genotipa.
Atsauces
Johnson GS, Mhlanga-Mutangadura T, Morava E, Kozicz T, Taylor JF, O’Brien DP, Schnabel RD. Canine Multiple System Degeneration is Associated with Distinct SERAC1 Mutations in Two Different Dog Breeds [abstract]. Presented at the 63rd Annual Meeting of the American Society of Human Genetics in Boston, Massachusetts; 2013 Oct 22-26.